Fluicell (Sweden) Performance
| FLUI Stock | SEK 0.06 0.01 13.60% |
The firm shows a Beta (market volatility) of -0.9, which means possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Fluicell are expected to decrease slowly. On the other hand, during market turmoil, Fluicell is expected to outperform it slightly. At this point, Fluicell AB has a negative expected return of -0.0555%. Please make sure to confirm Fluicell's skewness, accumulation distribution, and the relationship between the potential upside and kurtosis , to decide if Fluicell AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fluicell AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Fluicell is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 18.8 M | |
| Total Cashflows From Investing Activities | -772 K |
Fluicell |
Fluicell Relative Risk vs. Return Landscape
If you would invest 6.90 in Fluicell AB on October 26, 2024 and sell it today you would lose (1.90) from holding Fluicell AB or give up 27.54% of portfolio value over 90 days. Fluicell AB is generating negative expected returns and assumes 10.7065% volatility on return distribution over the 90 days horizon. Simply put, 95% of stocks are less volatile than Fluicell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Fluicell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fluicell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fluicell AB, and traders can use it to determine the average amount a Fluicell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0052
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FLUI |
Estimated Market Risk
| 10.71 actual daily | 95 95% of assets are less volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fluicell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fluicell by adding Fluicell to a well-diversified portfolio.
Fluicell Fundamentals Growth
Fluicell Stock prices reflect investors' perceptions of the future prospects and financial health of Fluicell, and Fluicell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fluicell Stock performance.
| Return On Equity | -1.13 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (8.62) % | |||
| Current Valuation | 49.13 M | |||
| Shares Outstanding | 24.49 M | |||
| Price To Book | 4.86 X | |||
| Price To Sales | 10.51 X | |||
| Revenue | 2.6 M | |||
| EBITDA | (21.08 M) | |||
| Cash And Equivalents | 20.69 M | |||
| Cash Per Share | 1.45 X | |||
| Debt To Equity | 0.19 % | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (18.64 M) | |||
| Earnings Per Share | (1.68) X | |||
| Total Asset | 26.98 M | |||
About Fluicell Performance
Assessing Fluicell's fundamental ratios provides investors with valuable insights into Fluicell's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Fluicell is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Fluicell AB provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company was founded in 2012 and is based in Gothenburg, Sweden. Fluicell operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 17 people.Things to note about Fluicell AB performance evaluation
Checking the ongoing alerts about Fluicell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fluicell AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fluicell AB generated a negative expected return over the last 90 days | |
| Fluicell AB has high historical volatility and very poor performance | |
| Fluicell AB has some characteristics of a very speculative penny stock | |
| Fluicell AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.6 M. Net Loss for the year was (21.69 M) with profit before overhead, payroll, taxes, and interest of 1.89 M. | |
| Fluicell AB has accumulated about 20.69 M in cash with (18.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Fluicell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fluicell's stock is overvalued or undervalued compared to its peers.
- Examining Fluicell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fluicell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fluicell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fluicell's stock. These opinions can provide insight into Fluicell's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Fluicell Stock Analysis
When running Fluicell's price analysis, check to measure Fluicell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fluicell is operating at the current time. Most of Fluicell's value examination focuses on studying past and present price action to predict the probability of Fluicell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fluicell's price. Additionally, you may evaluate how the addition of Fluicell to your portfolios can decrease your overall portfolio volatility.